Future of PrEP and Microbicide Research: Trial Design and Regulatory Issues

The Mayflower Renaissance Washington, DC Hotel
1127 Connecticut Ave NW
Washington, DC 20036
January 7, 2013

	SESSION	Speaker/Panelist
9:00 AM	**Welcome**	**Veronica Miller, HIV Forum** **Mitchell Warren, AVAC**
9:10 AM	**Session 1 -- Setting the stage (brief overview talks)**	**Moderator: Kenneth Mayer, Fenway Health**
	Overview of current PrEP (truvada) demonstration project; REMS update	**Jim Rooney, Gilead**
	Community Perspective on Uptake and Implementation of PrEP	**Jim Pickett, AIDS Foundation of Chicago**
	Overview of products in development (Oral/injectables)	**Trip Gulick, Weill Cornell Medical Center**
	Overview of products in development (Topical)	**Sharon Hillier, MTN**
10:25 AM	***BREAK***	
10:40 AM	**Session 2 -- Statistical Challenges**	**Moderator: Deborah Donnel, FHCRC**
	• Given the statistical requirements, what is the feasibility of conducting the size trials needed to show clinical efficacy of an HIV prevention modality? *• Are there any methods for economizing sample sizes?* *• From a statistical perspective, can tenofovir/emtricitabine serve as an active control.*	
	Microbicide Development Guidance	**Charu Mullick, FDA**
	Overview of statistical issues (non-inferiority, superiority, etc)	**Tom Fleming, SCHARP**
	EMA	**Nathalie Morgenszstejn, EMA**
	Panel discussion	
12:20 PM	***LUNCH***	
	Session 3 Clinical trial design options for trials assessing various delivery and dosing modalities	**Moderator: Veronica Miller, HIV Forum**
	• Following on from the previous discussion, what are the most clinically feasible trial design options (e.g., superiority, noninferiority, dose response) for HIV prevention trials? Do they differ according to method—topical microbicide vs. systemic? Do they differ according to population or risk group? *o For superiority studies, how should tenofovir/emtricitabine be positioned as part of background prevention treatment?* *o Must it be offered to all participants in an international trial, or only in regions where tenofovir/emtricitabine is approved or accepted?* *o Is it acceptable to conduct trials in subjects who do not elect to take tenofovir/emtricitabine, for whatever reason?* *o Does offering of background therapy differ according to prevention modality (topical vs. systemic)?* *• Can adherence measures be used to support the use of tenofovir/emtricitabine as an active control (to ensure assay sensitivity that the control is truly active in the population)?*	
	Overview of trial design options	**Deborah Donnell, FHCRC** **Jeff Murray, FDA**
	Panel discussion	**Manju Chatani, AVAC** **David Glidden, UCSF** **Sheena McCormack, MRC** **Jean-Michel Molina, ANRS**

2:35 PM	**Session 4 -- Adherence vs. Efficacy and Proof-of-Concept**	**Moderators: Alex Carballo-Dieguez, Columbia; Diane Rausch, NIMH**

•For proof-of-concept -- how can we distinguish between lack of signal due to potency vs adherence?

o How can adherence measurements be used to support efficacy claims for new drugs, new formulations, or dosing schemes?

• What are the most reliable measures of adherence?

• What role does evaluating systemic drug concentrations play in evaluating adherence and what are the limitations of using systemic drug concentrations to measure adherence?

• Instead of measuring systemic drug concentrations, are there alternative biological samples (e.g. PBMCs) that may provide more reliable measurements of adherence?

• Is there a role for patient-reported adherence measurements?

• For topical products, what are some other methods for measuring adherence?

• Is there a role for enriching trial enrollment with subjects deemed likely to be adherent? What are the pitfalls of this approach?

• How should ongoing assessments and interventions to improve adherence in clinical trials be factored into the analysis of efficacy?

	Panel discussion	**Rivet Amico, University of Connecticut** **David Burns, NIAID** **Robert Cuffe, ViiV Healthcare** **Bob Grant, UCSF** **Sybil Hosek, ATN** **Peter Miele, FDA** **Christina Psaros, Harvard**
3:30 PM	***BREAK***	
3:45 PM	**Session 5 -- "How do we get to surrogacy?"**	**Moderator: Jim Turpin, NIAID**

• What kind of non clinical studies and clinical PK/PD relationships can be used for making potential correlations with clinical efficacy?

		Damon Deming, FDA **Gustavo Doncel, CONRAD** ***Courtney Fletcher, UNMC (by phone)*** **Walid Heneine, CDC** **Joe Romano, NWJ Group** **Julie Strizki, Merck**
4:45 PM	**SUMMING UP: Is the future any clearer?**	**Mike Cohen, UNC** **James Goodrich, ViiV Healthcare**
4:55 PM	**NEXT STEPS**	**Veronica Miller, HIV Forum**
5:00 PM	***ADJOURN***	